2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 231

Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 459

Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 688

Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 645

Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 598

Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 629

Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 711

Recurrence of Lupus Nephritis in Renal Transplant Recipients

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 167

Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 101

Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 432

Relation of Patellofemoral Joint Alignment, Morphology, and Radiographic Osteoarthritis to Frequent Anterior Knee Pain

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 532

Relationship between Insulin Sensitivity and Beta Cell Secretion in Non-Diabetic Rheumatoid Arthritis Subjects

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 264

Relationships between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 663

Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 164

Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 643

Remission in Psoriatic Arthritis: Definition and Predictors

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].